6 results
The primary objective of this study is to test the hypothesis that treatment with LY3074828 is superior to placebo in inducing clinical remission at Week 12 in subjects with moderate to severe ulcerative colitis (UC).The secondary objectives are:-To…
To test the hypothesis that mirikizumab is superior to placebo in inducing clinical remission at Week 12 in patients with moderately to severely active ulcerative colitis (UC)
The purpose of the study is to investigate to what extent RO5459072 is safe and well tolerated.It will also be investigated how quickly and to what extent RO5459072 is absorbed, distributed to and removed from the body (this is called…
The purpose of the study is to investigate to what extent RO5459072 is safe and well tolerated. It will also be investigated how quickly and to what extent RO5459072 is absorbed, distributed to and removed from the body (this is called…
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
To test the hypothesis that mirikizumab is superior to placebo in maintaining clinical remission at Week 40 (Week 52 of continuous therapy) among patients induced into clinical remission with mirikizumab